Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring

J S J Thomas, H S Julian, R V Green, D A Cameron, M J Dixon

Research output: Contribution to journalArticlepeer-review

Abstract

Neoadjuvant systemic therapy of large and locally advanced breast cancers may, through shrinkage, enable breast conservation surgery. Letrozole, an aromatase inhibitor, is used frequently in the treatment of oestrogen receptor-positive breast cancer. The aim was to examine the response patterns in a letrozole-treated group compared with a chemotherapy-treated group.
Original languageEnglish
Pages (from-to)219-26
Number of pages8
JournalHistopathology
Volume51
Issue number2
DOIs
Publication statusPublished - Aug 2007

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Cicatrix
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Nitriles
  • Receptors, Estrogen
  • Triazoles

Fingerprint

Dive into the research topics of 'Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring'. Together they form a unique fingerprint.

Cite this